Skyrizi Denied by Insurance?
How to Appeal & Get Approved
Generic: risankizumab-rzaa
An IL-23 inhibitor for psoriasis and Crohn's disease — competing in a crowded biologic market.
- Used for
- Crohn's, UC
- Route
- 3 IV then SQ
- Specialty
- Gastroenterology
- PA Required
- Yes — 88% of prescriptions
Common Denial Reasons
Skyrizi is frequently denied for step therapy, documentation, and formulary reasons. Decode your specific denial →
require prior authorization before your pharmacy can fill them. If you've been denied, you're not alone — and most denials can be overturned on appeal.
Step Therapy Requirements
"Fail first" — what insurers require before approving Skyrizi
Most insurers require you to try alternative medications before approving Skyrizi. See your insurer's requirements →
Let Ellen Fight Your Skyrizi Denial
Ellen generates a personalized appeal letter for Skyrizi using your denial reason, insurer, and clinical situation.
- ✓Instant denial decoding — understand why you were denied
- ✓Payer-specific appeal language that matches your insurer's criteria
- ✓Clinical evidence suggestions your doctor can use
Insurance Coverage
Ellen tracks Skyrizi coverage across 39+ major insurers including formulary status, step therapy requirements, and common denial patterns.
Check your insurer's Skyrizipolicy →Safety Information
From FDA-approved prescribing information for Skyrizi (IL-23 Inhibitor)
Do Not Use If
- ✕Clinically significant hypersensitivity to risankizumab
Key Warnings
- ⚠Evaluate for TB before starting
- ⚠May increase risk of infections
This is not a complete list. See the full Skyrizi prescribing information or ask your pharmacist for comprehensive safety data.
Frequently Asked Questions
›Is Skyrizi better than Stelara?
Clinical trials (IMMerge) showed Skyrizi achieved higher skin clearance rates than Stelara for psoriasis. However, insurance coverage depends on your plan's formulary. If one is denied, your dermatologist can try the other or appeal.
›Does Skyrizi work for Crohn's disease?
Yes, Skyrizi is FDA-approved for moderately-to-severely active Crohn's disease. It requires 3 IV induction doses (weeks 0, 4, 8) followed by subcutaneous maintenance injections every 8 weeks.
›What does Skyrizi step therapy look like?
For psoriasis: fail conventional systemic therapy, meet BSA thresholds (≥10% or crucial body areas). For Crohn's: documentation of moderately-to-severely active disease. Some plans require TNF inhibitor failure before any IL-23 inhibitor.